arising from Kateřina Menšíková et al. npj Parkinson's Disease https://doi.org/10.1038/s41531-021-00273-9 (2022)
Menšíková et al.1 in their recent review of Lewy body disease, emphasized (a) that from the strict pathological point of view, there is practically no difference between PD and PDD, even the experienced neuropathologist is not able to differentiate; and (b) that there is no sharp pathological border between PDD and DLB, although the degree of AD pathology and the presence of CAA are probably the most significant pathological differences between these two phenotypes. These two statements need some discussion based on personal and other recent data about the complex relations between cognitive impairment and neuropathology in LB diseases. Ad (a): In a personal autopsy series of 330 PD patients, only 3.2% of demented ones (37.6% of the total cohort) had Braak LB stages 2–3 with severe AD co-pathology (neuritic Braak stages V and VI), while 35.5% of demented PD patients revealed LB stages 4 or 5 with superimposed neuritic Braak stages V and VI. More than 50% of them showed a strong relationship between the severity of αSyn and tau pathologies, particularly in the limbic system. LB pathology with moderate or high grade AD lesions was seen in 40% of PDD patients, while one third of cases with diffuse LB pathology and mild AD lesions, restricted to Aβ plaques of limbic tau pathology, did not show considerable cognitive impairment2. PDD patients had significantly lower brain weight than non-demented ones, while significantly more severe Alzheimer neuropathological changes were present in PDD than non-demented (ND) PD patients3. In another study of 60 ND-PD and 110 PDD patients, the latter were significantly older than ND-PD ones—83.9 vs. 77.8 years; p < 0.01), PDD showed only slightly higher Braak LB scores (mean 4.2 vs. 4.0), but significantly higher neuritic Braak stages (mean 5.2 vs. 4.4), Thal Aβ phases (mean 3.0 vs. 2.3), and both significantly higher CAA frequency and severity (50% vs. 21.7% and mean 0.72 vs. 0.26). In conclusion, association between cortical Aβ load, generalized CAA and tau pathology are the morphological basis of cognitive decline in PD4.
Ad (b): There is general agreement that both PDD and DLB share neuropathological features, with a variable mixture of LB and AD-related co-pathologies. However, recent studies have shown some essential morphological differences between PDD and DLB, that is, more frequently increased cortical and striatal Aβ load5, more severe cortical tau pathology (Braak 5.1 ± 0.7 vs. 4.2 ± 0.4), and higher CAA frequency and severity (91% vs. 50% and 2.3 ± 0.2 vs. 0.72 ± 0.2; both p < 0.01), the latter mainly in occipital and less in frontal lobes4,6. Most frequent and highest CAA scores were seen in cases with APOE ε4 (PDD 33.3%, DLB 48%)7. Cortical tau pathology was also more frequent in DLB, the incidence of negative cases being 70% vs. 82% in PDD, also supporting the notion that the morphological distinction between the two phenotypes is not restricted to Aβ deposition, cortical LB and tau pathologies8. Further differences are more severe αSyn load in hippocampal subareas CA 2/3 and entorhinal cortex (EC) implicating the role of the EC-CA circuitry in the pathogenesis of DLB9. There is different involvement of substantia nigra, with more severe neuronal loss in ventrolateral cell groups in PD, but predominant damage of dorsolateral ones in DLB10, causing less severe postsynaptic dopaminergic upregulation, while significantly higher 5-HT1A receptor-binding density in cortex is seen in DLB compared to PDD11. DLB showed worse prognosis than PDD (mean survival mean 6.7 vs. 12.5 years; p < 0.01), which was linked to both increased tau and CAA pathologies distinguishing both disorders. The reasons for these clinical and pathological differences between the phenotypes, PD, PDD and DLB(+AD) are not clear, but recent studies suggest a close interaction of the various pathological proteins, in particular between αSyn, Aβ and tau12 within the spectrum of LB diseases (or diseases with LBs)13. Cerebrovascular co-pathologies, in particular cerebral microbleeds, showed a similar prevalence in PDD, DLB and AD14, although recent studies suggested a synergistic interaction between cerebrovascular disease and Lewy pathologies, which possibly extends to other highly concomitant pathologies in LB disorders15. In conclusion, it should be emphasized that other co-pathologies may influence the clinical features and progression in both PDD and DLB16. The impact of all of them, however, needs further elucidation.
References
Menšíková, K. et al. Lewy body disease or diseases with Lewy bodies? NPJ Parkinsons Dis. 8, 3 (2022).
Jellinger, K. A. Morphological substrates of parkinsonism with and without dementia: a retrospective clinico-pathological study. J. Neural Transm. Suppl. 72, 91–104 (2007).
Jellinger, K. A. The neuropathologic substrate of Parkinson disease dementia. Acta Neuropathol. 119, 151–153 (2010).
Jellinger, K. A. Significance of cerebral amyloid angiopathy and other co-morbidities in Lewy body diseases. J. Neural Transm. 128, 687–699 (2021).
Jellinger, K. A. & Attems, J. Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies? Acta Neuropathol. 112, 253–260 (2006).
Hansen, D. et al. Novel clinicopathological characteristics differentiate dementia with Lewy bodies from Parkinson’s disease dementia. Neuropathol. Appl Neurobiol. 47, 143–156 (2021).
Jellinger, K. A. Morphological differences between dementia with Lewy bodies and Parkinson’s disease-dementia. Neuropathol. Appl Neurobiol. 48, e12708 (2021).
Jellinger, K. A. Significance of brain lesions in Parkinson disease dementia and Lewy body dementia. Front. Neurol. Neurosci. 24, 114–125 (2009).
Jellinger, K. A. Neuropathology of Parkinson’s disease. in Inflammation in Parkinson’s Disease: Scientific and Clinical Aspects (ed Thomas, M.) 25–47 (Springer, New York, 2014).
Dickson, D. W. et al. Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria. Lancet Neurol. 8, 1150–1157 (2009).
Francis, P. T. & Perry, E. K. Cholinergic and other neurotransmitter mechanisms in Parkinson’s disease, Parkinson’s disease dementia, and dementia with Lewy bodies. Mov. Disord. 22(Suppl 17), S351–S357 (2007).
Miller, R. L. et al. Quantifying regional alpha-synuclein, amyloid beta, and tau accumulation in Lewy body dementia. Ann. Clin. Transl. Neurol. 9, 106–121 (2022).
Jellinger, K. A. Dementia with Lewy bodies and Parkinson’s disease-dementia: current concepts and controversies. J. Neural Transm. 125, 615–650 (2018).
Hijazi, Z., Yassi, N., O’Brien, J. T. & Watson, R. The influence of cerebrovascular disease in dementia with Lewy bodies and Parkinson’s disease dementia. Eur. J. Neurol. 29, 1254–1265 (2021).
Ferreira, D. et al. Cerebrovascular disease, neurodegeneration, and clinical phenotype in dementia with Lewy bodies. Neurobiol. Aging 105, 252–261 (2021).
Walker, L., Stefanis, L. & Attems, J. Clinical and neuropathological differences between Parkinson’s disease, Parkinson’s disease dementia and dementia with Lewy bodies - current issues and future directions. J. Neurochem. 150, 467–474 (2019).
Acknowledgements
The study was funded by the Society for the Promotion of Research in Experimental Neurology, Vienna, Austria.
Author information
Authors and Affiliations
Contributions
K.A.J. is the sole author. E.M.-F. contribution was operating office software and online submission.
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Jellinger, K.A. Matters Arising ‘Lewy body disease or diseases with Lewy bodies?’. npj Parkinsons Dis. 8, 81 (2022). https://doi.org/10.1038/s41531-022-00337-4
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41531-022-00337-4